AI Article Synopsis

  • - The study aimed to explore how certain immune system markers before surgery relate to the chances of esophageal squamous cell carcinoma (ESCC) returning within three years after patients undergo immunotherapy and chemotherapy.
  • - Researchers analyzed 348 ESCC patients, comparing those who experienced recurrence to those who did not, looking at various immunological factors and lifestyle choices that could impact recurrence risk.
  • - Key findings indicated that higher levels of CD8+ and Perforin+ cells were linked to a lower recurrence risk, while certain proteins (like EGFR and PD-L1) correlated with a higher risk; a predictive model showed high accuracy for assessing recurrence based on these markers.

Article Abstract

Objective: To investigate the association between preoperative immunological biomarkers and risk of esophageal squamous cell carcinoma (ESCC) recurrence within 3 years after combined immunotherapy and neoadjuvant chemotherapy.

Methods: This retrospective case-control study included 348 ESCC patients who received immunotherapy and neoadjuvant chemotherapy in Henan Provincial People's Hospital between 2021 and 2023. Patients were divided into a recurrence (n=197) group and a non-recurrence (n=151) group based on their recurrence within 3 years. Tumor-infiltrating lymphocytes, serum tumor-specific antibodies, immune checkpoint expression, and HLA expression were analyzed and compared between groups. Correlation and regression analyses evaluated associations between biomarkers and recurrence risk. Then, a joint prediction model was established.

Results: The study revealed that CD8+ and Perforin+ cell percentages were significantly associated with a lower risk of recurrence (P<0.001), while EGFR, HER2, p53, PD-L1, CTLA-4, Tim-3, and LAG-3 were linked to an increased risk of recurrence (P<0.001). Lifestyle factors like salted food consumption, regular hot drink intake, gastric atrophy, and vitamin A deficiency also contributed to ESCC recurrence prediction (all P<0.05). A predictive model incorporating immune markers and risk factors for predicting ESCC recurrence within three years post-treatment demonstrated an AUC of 0.986.

Conclusion: Immunological biomarkers, including tumor-infiltrating lymphocytes, serum tumor antibodies, immune checkpoint expression, and HLA expression are associated with ESCC recurrence risk within 3 years of combined immunotherapy and neoadjuvant chemotherapy. These biomarkers may help stratify patients and guide management decisions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560828PMC
http://dx.doi.org/10.62347/ELRQ9964DOI Listing

Publication Analysis

Top Keywords

immunotherapy neoadjuvant
12
immunological biomarkers
8
esophageal squamous
8
squamous cell
8
cell carcinoma
8
combined immunotherapy
8
neoadjuvant chemotherapy
8
recurrence years
8
recurrence
6
biomarkers predictive
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!